Circulating endothelial progenitor cells (CEPC) are supposed to be a subset of bone marrowderived pe ripheral blood mononuclear cells (PBMC), revealing immature surface markers common to hematopoietic stem cells, such as CD 34 and CD 133 and endothe lial lineage markers. These cells can be isolated from peripheral, umbilical cord, and bone marrow blood. CD 34 represents a marker of immature stem cells that is commonly used to characterize CEPC together with other surface antigens. Though, as CD 34 is also expressed at lower levels on mature endothelial cells, most recent studies used CD 133, a marker of more immature hematopoietic stem cells that is now considered the best surface marker to define, identify and isolate the CEPC 1 . CD 133 (also known as AC 133 or prominin) is highly conserved antigen with un known biological activity. It would be expressed on he matopoietic stem cells, but not on mature endothelial cell and monocytes. In order to reflect the endothelial cells, there is general agreement for the use of at least one additional marker, such as vascular endothelial growth factor receptor-2 (VEGFR2 or KDR), while others are platelet-endothelial cells adhesion molecules-1 (PECAM1), von Willebrand factor, ckit, Tie2, vascular endothelial-cadherin and VEGFR1 2 .
The pivotal role shown by the endothelial cells in cardiovascular (CV) biology has been becoming increasingly appreciated. Endothelial injury has been involved in atherosclerosis,thrombosis, and hyperten sion, and the balance between endothelial injury and endothelial recovery is of supreme importance for reducing CV events. Further, other studies are also providing intriguing and encouraging insight into the potential use of CEPC in the clinical setting.Indeed, there is accumulating evidence for reduced availabil ityand impaired CEPC function in the presence of both CV disease and associated comorbid risk factors 3 with endothelial dysfunction.
Endothelial dysfunction, detected as the presence of reduced vasodilating response to endothelial stimuli, has been observed to be associated with major CV risk factors, such as aging, diabetes, hypercholesterolemia, hypertension, smoking, hyperhomocysteinemia, and postmenopause state 4, 5 . Accordingly, endothelial func tion is proved to be associated with the number of CV risk factors and therefore with the global CV risk. This was also confirmed in the Framingham population, in which an escalating inverse relationship between endothelialdependent relaxation, estimated by flowmediated dilatation (FMD) and the CV risk score.
Multiple studies have consistently reported an association between lipid metabolism and the biol ogy ofhuman EPC. The numbers of EPC colony forming unitsare significantly reduced in relatively healthy subjects with hypercholesterolemia 5 . In CAD, lowdensitylipoprotein (LDL) cholesterol inversely correlates with the number of CEPC. In addition, the functional characteristics of isolated EPC, such as proliferation, migration, adhesion, and in vitro vas culogenic capacity, are also impaired in patients with hypercholesterolemia 5 .
Among several CV risk factors, hypertension is the strongest predictor of CEPC migratory impairment. Angiotensin II reduces telomerase activity in CEPC and accelerates the onset of CEPC senescence via an enhanced oxidative stress 6 . Although angiotensin II inhibited CEPC proliferation in one study, but it in crease VEGFinduced EPC proliferation in another. Angiotensin II also potentiates VEGFinduced net work formation by CEPC, maybe by upregulation of KDR. Angiotensin II likely would induce increased shear stress, and subsequently it increases differentia tion, adhesion, migration, proliferation, antiapoptosis, and vasculogenesis of CEPC by activation of VEGFR2 and signal transduction pathway 7 .
Diabetes mellitus, another important CV risk factor, is a disease in which impairment of ischemia induced neovascularization has been described. The number of CEPC is reduced in diabetes 1 . Further more, marked CEPC dysfunction may underlie new mechanisms involved in the pathogenesis of vascular complications in diabetic patients 1 . Diminished CEPC supplied by diabetes may be ascribed to impaired CEPC production in bone marrow and to decreased CEPC mobilization from spleen, which may contrib ute to endothelial dysfunction in diabetes 8 . Further evidence of the adverse impact of hyperglycemiaon CEPC was shown by Kränkel et al. 9 , who demonstra ted that cultivation of PBMNC from healthy donors under hyperglycemic conditionswas associated with significant reduction in CEPC numbers, inhibition of NO production, and matrixmetalloproteinase9 activity, as well as an impairment of them igrational and integrative capacities of the cells.
In order to prove the reality in our own popula tion in Indonesia, one of the investigators recently had conducted the study and published in this journal. They recruited 55 subjects (normal subjects, those with CVD risk and CVD subjects) and divided them into 6 groups, based on "Framingham risk score'. CEPC was measured by flow cytometry, and confirmed using CD 34 Per CP Santa Cruz SC19621 and CD 133 FITC (fluorescein isothiocyanate) Bioss bs0395RFITC. Fur ther, to indicate circulating endothelial cells (CEC), they were measured using CD45 FITC Biolegend 202205 and CD 146 PE Biolegend 134704 marker.
Unpredictably, the study suggested that: 'increased EPC was associated with increased CVD risk based on the Framingham risk score'. This finding unfortu nately did not confirm the previous available studies. This might be explained by such following: "CEPC count in vitro does not provide information on the absolute number of CEPC 10 , because they depend not only on the initial number of progenitors, but also on adhesion, proliferation and survival of plated EPC, resulting from complex in vivo cellular interactions. These considerations suggest that it may be difficult to define the "true" population of CEPC and reflects in vivo setting 2 . Anyway, we appreciated with this initia tive to conduct the study, as the proverb says: 'better to light a candle than to curse the darkness'.
